Evidence map›Paper›PMID 37289055›Full record

ArticleJournal of virology2023

Nydia C De La Cruz, Maureen Möckel, Hanna Niehues, Matthias Rübsam, Wolfram Malter, Max Zinser, Claude Krummenacher, Dagmar Knebel-Mörsdorf

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Nydia C De La CruzCenter for Biochemistry, University Hospital Cologne, University of Cologne, Cologne, Germany.
Maureen MöckelCenter for Biochemistry, University Hospital Cologne, University of Cologne, Cologne, Germany.
Hanna NiehuesDepartment of Dermatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Matthias RübsamDepartment Cell Biology of the Skin, University Hospital Cologne, University of Cologne, Cologne, Germany.
Wolfram MalterDepartment of Gynecology and Obstetrics, University Hospital Cologne, University of Cologne, Cologne, Germany.
Max ZinserDepartment of Plastic, Reconstructive and Aesthetic Surgery, University Hospital Cologne, University of Cologne, Cologne, Germany.
Claude KrummenacherDepartment of Biological and Biomedical Sciences, Rowan University, Glassboro, New Jersey, USA.ORCID 0000-0002-3492-4987
Dagmar Knebel-MörsdorfCenter for Biochemistry, University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-0038-5030
University of Cologne · DERadboud University Nijmegen · NLRowan University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herpes simplex virus 1 (HSV-1) must overcome epidermal barriers to reach its receptors on keratinocytes and initiate infection in human skin. The cell-adhesion molecule nectin-1, which is expressed in human epidermis, acts as an efficient receptor for HSV-1 but is not within reach of the virus upon exposure of human skin under nonpathological conditions. Atopic dermatitis skin, however, can provide an entry portal for HSV-1 emphasizing the role of impaired barrier functions. Here, we explored how epidermal barriers impact HSV-1 invasion in human epidermis and influence the accessibility of nectin-1 for the virus. Using human epidermal equivalents, we observed a correlation of the number of infected cells with tight-junction formation, suggesting that mature tight junctions prior to formation of the stratum corneum prevent viral access to nectin-1. Consequently, impaired epidermal barriers driven by Th2-inflammatory cytokines interleukin 4 (IL-4) and IL-13 as well as the genetic predisposition of nonlesional atopic dermatitis keratinocytes correlated with enhanced infection supporting the impact of functional tight junctions for preventing infection in human epidermis. Comparable to E-cadherin, nectin-1 was distributed throughout the epidermal layers and localized just underneath the tight-junctions. While nectin-1 was evenly distributed on primary human keratinocytes in culture, the receptor was enriched at lateral surfaces of basal and suprabasal cells during differentiation. Nectin-1 showed no major redistribution in the thickened atopic dermatitis and IL-4/IL-13-treated human epidermis in which HSV-1 can invade. However, nectin-1 localization toward tight junction components changed, suggesting that defective tight-junction barriers make nectin-1 accessible for HSV-1 which enables facilitated viral penetration.

Indexed as

Dermatitis, AtopicHerpes SimplexHerpesvirus 1, HumanNectinsTight JunctionsEpidermisHumansInterleukin-13Interleukin-4Interleukin-13Interleukin-4NECTIN1 protein, humanNectinsepidermal barriersepidermal equivalentsHSV-1human keratinocyteshuman skinIL-4/IL-13nectin-1nonlesional atopic dermatis keratinocytesnonlesional atopic dermatitis skinN/TERT-1 cellsprimary human keratinocytestight junctionsvirus entry

Identifiers

PMID37289055
PMCPMC10308952
OpenAlexW4379768602

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.